Peptide Stacking Guide

A stack is two or more compounds used together on the premise that they do different things which combine usefully. That premise is the whole argument, and it is worth stating plainly at the outset that for peptides it is almost never a tested premise. Across the entire catalog covered by this guide, the number of combinations evaluated in a controlled human trial is essentially one — cagrilintide with semaglutide, which is in formal clinical development as a single product. Everything else is inference.

That does not make stacking irrational. Combining agents with distinct mechanisms is standard practice in medicine, and the reasoning transfers. What does not transfer is the confidence: in medicine those combinations are tested before they are recommended, and here they are not. So the useful question is never 'is this stack good' but 'what specifically is each component contributing, and how would I know if it were not contributing anything'.

Four questions separate a combination with a rationale from a combination that is just two purchases. First, do the components act through genuinely different mechanisms, or are they two routes to the same receptor? Second, is each one dosed on its own reported scale, or is one being carried along at whatever amount the other happens to need? Third, could you tell which component produced an effect — and if not, why are both present? Fourth, does either component have a constraint the other does not, such as cumulative exposure or an approval status that governs how it must be handled?

Most published and community stack advice fails the third question. A four-component blend administered as one draw cannot answer it in principle, because no component can be varied independently. That is not a reason to avoid blends, but it is a reason to be honest that a blend is a bet on the whole formulation rather than a protocol you are controlling.

Three blend names dominate discussion, and they are the same core with progressively more added. Understanding them as a family rather than three separate products removes most of the confusion around them — including the frequent mislabelling of one as another.

Wolverine is BPC-157 plus TB-500: repair signaling paired with cell migration. GLOW adds GHK-Cu, which contributes copper-driven matrix remodeling and collagen synthesis — a genuinely different mechanism rather than more of the same. KLOW adds KPV on top of that, contributing anti-inflammatory signaling and shifting the stated focus toward gut and inflammatory contexts.

Each addition therefore answers the first foundational question well: the components do different things. Where the family fails is the third question. All three are commonly sold as pre-mixed vials, and a pre-mixed vial fixes the ratio of every component to every other. You are choosing a formulation, not running a protocol.

There is also a live definitional disagreement worth knowing. A minority of sources define KLOW as KPV plus BPC-157 only — two components rather than four. The four-component definition is dominant and matches the 80 mg blend products on the market, but if a protocol, a dose figure or a vendor listing does not state its component list, it cannot be assumed to mean the same thing as another source using the same name.

Beyond the named blends, combinations are grouped by the research context they belong to. What follows describes how each grouping is constructed and where its reasoning is weakest — which is usually more useful than a list of pairings.

Repair and soft tissue. BPC-157, TB-500, GHK-Cu, KPV. The best-developed grouping and the basis of the named blends. Its strength is mechanistic diversity; its weakness is that all four have thin human data and the scale differences between them (micrograms for BPC-157, milligrams for the others) are a persistent source of arithmetic error.

Growth-hormone axis. CJC-1295, Mod GRF 1-29, Sermorelin, Tesamorelin, Ipamorelin, GHRP-2, GHRP-6, Hexarelin. This grouping has the clearest internal logic of any here: a GHRH analog paired with a ghrelin-receptor secretagogue acts on two distinct upstream pathways, which is why CJC-1295 with Ipamorelin is the canonical example. It also has the clearest redundancy trap — see the class-collision section below.

Metabolic and weight management. Semaglutide, Tirzepatide, Retatrutide, Cagrilintide. This is the grouping where stacking language is least appropriate. Semaglutide and tirzepatide are approved prescription medicines with boxed warnings, documented contraindications and real interaction profiles; tirzepatide is already a dual agonist in a single molecule. Combining incretin therapies is a clinical decision, not a stacking choice, and the one formally studied combination here (cagrilintide with semaglutide) is being developed as a single regulated product precisely because that is how combinations get evidence.

Skin and aesthetics. GHK-Cu, AHK-Cu, Melanotan I and II. The distinguishing feature of this grouping is a route mismatch: the strongest human evidence for copper peptides is topical, while the stacks are discussed as injections. The melanocortin compounds carry their own separate and well-documented safety considerations.

Cognition, mood and sleep. Semax, Selank, DSIP, and the amidated variants. Semax and Selank are genuinely complementary in framing — focus versus anxiety — and both come from the same Russian research tradition. Two caveats apply to the whole grouping: the evidence base is concentrated in one national literature with limited independent replication, and the published research is predominantly intranasal rather than injected.

Mitochondrial and longevity. MOTS-c, SS-31, NAD+, Epithalon, Thymalin, Cartalax. Mechanistically the most heterogeneous grouping. The Khavinson bioregulators (Epithalon, Thymalin, Cartalax) share a research tradition whose central mechanistic claim — short peptides binding DNA promoter regions directly — is not a broadly accepted model, and whose literature comes overwhelmingly from one laboratory.

The most frequent error in peptide stacking is not a dangerous interaction — it is paying twice for one mechanism. Two compounds acting on the same receptor by the same route do not generally add; they compete for the same finite response, and the ceiling is set by the pathway rather than by the dose.

The growth-hormone axis is where this happens most. GHRH analogs — Sermorelin, CJC-1295, Mod GRF 1-29, Tesamorelin — all act at the GHRH receptor. Pairing two of them is widely described as redundant, and it is worth being specific about why: Mod GRF 1-29 *is* CJC-1295 without the DAC modification, so 'CJC-1295 plus Mod GRF' is close to running one compound against itself with different kinetics. Likewise the ghrelin-receptor secretagogues — Ipamorelin, GHRP-2, GHRP-6, Hexarelin — act at GHS-R1a; stacking two of those is the same error on the other pathway. The coherent construction takes one from each class, not two from either.

The same logic applies elsewhere. Two copper-carrying peptides used systemically (GHK-Cu with AHK-Cu) compound cumulative copper exposure without adding a mechanism. Two incretin agonists duplicate GLP-1 signaling — and tirzepatide already contains two mechanisms in one molecule, which is a point often missed when it is proposed as an addition to something else. Semax with N-Acetyl Semax Amidate is the same compound in two forms.

A practical test: name the receptor or pathway each component acts on. If two components name the same one, the burden is on the rationale to explain what the second adds that the first does not — different kinetics can be a legitimate answer, but 'more' generally is not.

Interactions between research peptides are, with very few exceptions, unstudied rather than known to be absent. This is the single most important thing to hold onto when reading stack content, because absence of reported interactions in a literature that has never looked for them is not evidence of safety. Most peptides in this catalog have limited human data individually; combination data essentially do not exist.

There are, however, three places where interaction risk is genuinely documented, and they deserve separate treatment from the general 'unstudied' category.

Approved medicines in the stack. Semaglutide and tirzepatide have full prescribing information, including contraindications (personal or family history of medullary thyroid carcinoma, MEN 2), boxed warnings, and documented interactions — notably increased hypoglycaemia risk when combined with insulin or sulfonylureas, and reduced oral-contraceptive efficacy after tirzepatide's first dose owing to delayed gastric emptying. These are real, characterised interactions, not theoretical ones, and they are not altered by the fact that a research-market vial was used instead of a pharmacy product.

Compounds that alter absorption or clearance. Anything that slows gastric emptying changes the absorption of everything taken orally alongside it. This is why the incretin compounds interact with oral medications as a class rather than as individuals, and it is the mechanism behind the contraceptive interaction above.

Cumulative-exposure compounds. Copper peptides are the clearest example: GHK-Cu and AHK-Cu deliver copper, copper accumulates, and copper overload has established toxicity. The risk is not an interaction between two peptides so much as a dose-summing problem that stacking makes invisible — two vials each at a modest amount is not a modest total.

Beyond those three, the honest position is that a combination's risk profile is the union of its components' individual profiles plus an unquantified unknown. For blends, add that the per-component amounts vary by vendor, so the union itself is not fixed.

Pre-mixed blends are sold by their combined mass. An 80 mg KLOW vial contains 80 mg of four peptides *in total*, not 80 mg of each. Dividing that total by the water volume added therefore yields total peptide concentration — a number with no practical use, because you never administer 'total peptide'.

To get any individual component's concentration you need the per-component split, and vendors do not standardise it. Two 80 mg vials from different suppliers can contain materially different amounts of each peptide. The consequence is specific and worth stating bluntly: a volume figure taken from a forum post, a vendor page or another vial's documentation only ever applied to that vial's split. Carrying it across is not an approximation, it is an unrelated number.

There is a second, subtler consequence. Because all components share one solution, one draw delivers a fixed ratio of every component simultaneously. You cannot raise one and hold the others constant. If a component turns out to be the one you did not want, the only lever is the whole blend. This is the structural difference between a blend and separate vials, and it is a reason to prefer separate vials when the components' reported scales differ widely — as they do for BPC-157 (micrograms) against TB-500 and GHK-Cu (milligrams).

The method for a blend, once the split is known, is simply the single-vial method applied per component: component mass divided by water volume gives that component's mg/mL, and on a U-100 syringe 100 units equals 1 mL. Do it once per component and check that every resulting figure is drawable — if a component's target amount exceeds 100 units at your chosen water volume, the water volume is wrong for that vial.

Cycling is discussed as though it were one practice, but the reported rationales are distinct and apply to different compounds. Treating them as interchangeable produces protocols that take breaks for no reason, or fail to take them where there is one.

Receptor desensitisation. The rationale for growth-hormone secretagogues. Continuous stimulation of GHS-R1a is described as reducing responsiveness, which is why reported protocols use defined blocks and why pulsatile timing is emphasised. This is the closest to a mechanistic rationale in the group.

Cumulative exposure. The rationale for copper peptides. Copper accumulates; breaks limit total load. This one is about the accompanying metal rather than the peptide, and it is why GHK-Cu-containing blends are described with defined breaks more consistently than the non-copper repair stacks.

Study design inheritance. The rationale for the Khavinson bioregulators — Epithalon, Thymalin, Cartalax. Reported courses of 10 to 20 days repeated once or twice yearly reflect how the original Russian studies were structured, not an established pharmacological requirement. It is worth knowing the difference: this is convention, not a demonstrated need.

Not cycled at all. The approved metabolic medicines. Semaglutide and tirzepatide are titrated upward and then continued; their labels describe ongoing treatment, and weight regain after discontinuation is documented. Applying research-peptide cycling conventions to them misreads what they are.

For repair stacks the common pattern is a defined block of weeks aligned to a specific research objective rather than open-ended use — which also happens to be the only structure under which you could notice whether the stack did anything.

A stack rationale is worthless if the vials do not contain what the label says. This is not a hypothetical concern in this market, and it interacts with stacking in a specific way: blends conceal identity problems that separate vials would expose.

The clearest single case is TB-500. It is a synthetic 7-amino-acid fragment (Ac-LKKTETQ) of the 43-amino-acid Thymosin Beta-4 protein, and the two are widely conflated by vendors. They are different molecules with different reported scales, so a protocol written for one does not apply to the other. Mass spectrometry on a certificate of analysis is what distinguishes them; a purity figure alone does not, because purity answers 'how much of this vial is one substance' and not 'which substance is it'.

That distinction matters generally. A COA showing 99% purity with no identity confirmation tells you the vial is consistently something. Identity — mass spec, ideally with the expected molecular weight stated — is the part that matters for a stack, because the entire rationale rests on which molecules are present.

For blends the problem compounds twice over: you are trusting both the identity of four components and their ratio, and the ratio is the part no vendor is obliged to standardise. If a blend's documentation does not state a per-component split, the honest description of what you have is 'four peptides in unknown proportion'.

Reconstitution introduces its own integrity question, separate from identity. Use USP-grade bacteriostatic water — the 0.9% benzyl alcohol preservative is what permits a multi-dose vial to be entered repeatedly — add it slowly down the vial wall, and swirl rather than shake. Peptides are shear- and heat-sensitive; vigorous agitation and foaming are avoided for that reason.

Most of what circulates about peptide stacking is written to sell something, and the tells are consistent. These are the signals worth applying to any source, including this one.

A specific outcome figure with no citation. Percentages and timeframes attached to a combination are the strongest single tell, because no controlled trial has produced them for any stack in this catalog.

A named study that cannot be located. Suspiciously precise pharmacokinetic figures — half-life, bioavailability — circulating only on commercial sites, with no traceable publication. If a specific number appears in marketing but not in PubMed, treat it as marketing.

Confident dosing for a blend without a stated split. As above, this is arithmetically impossible. A source giving blend volumes without component masses either does not understand the calculation or is not doing one.

Class collisions presented as synergy. Two GHRH analogs, or two GHS-R1a secretagogues, described as complementary. This is a competence signal about the source.

Approved medicines discussed with research-peptide conventions. Cycling advice for semaglutide, or stacking language around tirzepatide, indicates the source is not distinguishing a regulated medicine from a research chemical.

Silence on what a component contributes. If a stack's description does not say what each component is for, the honest reading is that the list is a bundle rather than a rationale.

Absence of the word 'reported'. Content that states community practice as established fact is not distinguishing between the two, which means you cannot rely on it to tell you where the evidence ends.